29 November 2023 Scandion Oncology is granted new Composition of Matter-patent on lead compound SCO-101 extending its exclusivity until at least 2042 Download Presentation Webcast Workbook
21 November 2023 Final data from the Phase IIa open-label CORIST part 2 trial shows impressive median Overall Survival of 10.4 months Download Presentation Webcast Workbook
15 November 2023 Invitation to Scandion Oncology webcast and conference call November 22, 2023 Download Presentation Webcast Workbook
16 October 2023 Phase Ib PANTAX trial is successfully completed and establishes the maximal tolerated dose with positive safety profile and pharmacokinetic data. Download Presentation Webcast Workbook
12 September 2023 Scandion Oncology appoints Lars Damstrup, MD, PhD, as new Chief Medical Officer Download Presentation Webcast Workbook
17 August 2023 Data from PANTAX trial to be presented at ESMO Congress 2023 Download Presentation Webcast Workbook
16 August 2023 Invitation to Scandion Oncology webcast and conference call August 23, 2023 Download Presentation Webcast Workbook
18 July 2023 The European Patent Office announces intention to grant of Composition-of-Matter patent for Scandion Oncology’s lead compound SCO-101 Download Presentation Webcast Workbook
19 May 2023 Invitation to Scandion Oncology webcast and conference call May 26, 2023 Download Presentation Webcast Workbook